Dermatology News Archive: 2006

• 2006(37) Single-Day Therapy for Recurrent Genital Herpes
  Genital herpes, an incurable viral disease that can have a devastating impact on affected patients, is a serious public health concern affecting one in four Americans. Episodic treatment with nucleoside analogs for 3-5 days is the most common method of treatment   |   Read more ...



• 2006(36) Management of Cutaneous Dermatomyositis: Current Therapeutic Options
  Dermatomyositis is an idiopathic inflammatory myopathy with characteristic cutaneous manifestations and proximal muscle weakness. Patients with this condition frequently require treatment for muscular, systemic, and cutaneous involvement   |   Read more ...



• 2006(35) Intravenous Immunoglobulin Use in Patients with Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome
  Intravenous immunoglobulin (IVIg) has been proposed as a treatment for toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS). A comprehensive search of the literature was conducted to examine the efficacy and safety of IVIg in TEN and SJS patients   |   Read more ...



• 2006(34) Oral Antifungal-Exacerbated Inflammatory Flare-Up Reactions of Dermatomycosis: Case Reports and Review of the Literature
  Acne is traditionally regarded as a skin disorder of the teenage years. However, recent epidemiologic studies have shown that a significant number of female patients aged >25 years experience acne. One recent community-based UK study estimated the prevalence of facial acne in adult women aged between 26 and 44 years to be 14%   |   Read more ...



• 2006(33) Persistent Acne in Women: Implications for the Patient and for Therapy
  Acne is traditionally regarded as a skin disorder of the teenage years. However, recent epidemiologic studies have shown that a significant number of female patients aged >25 years experience acne. One recent community-based UK study estimated the prevalence of facial acne in adult women aged between 26 and 44 years to be 14%   |   Read more ...



• 2006(32) Role of Bacterial Superantigens in Atopic Dermatitis: Implications for Future Therapeutic Strategies The role of staphylococcal superantigens in the pathophysiology of atopic dermatitis (AD) has been the focus of intense interest during the past decade. Although the increased prevalence of Staphylococcus aureus and its bacterial toxins in AD skin is well established   |   Read more ...



• 2006(31) Increased Hair Shedding May be Associated with the Presence of Pityrosporum ovale
  Although the available data show that hair loss is an important cosmetic problem worldwide, the pathogenesis of common hair shedding is not fully understood. The aim of this study was to evaluate the association between hair shedding and cutaneous Malassezia infection   |   Read more ...



• 2006(30) The Role of Antimalarials in the Exacerbation of Psoriasis: A Systematic Review
  MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were reviewed to identify English-language publications from 1966-2005 examining the role of antimalarials in the exacerbation of psoriasis   |   Read more ...



• 2006(29) A Comprehensive Review of the Long-Term and Short-Term Treatment of Melasma with a Triple Combination Cream
  Melasma is a common disorder of hyperpigmentation and generally involves areas of the face and neck. Hyperpigmentation is especially prevalent in darker complected patients and is often difficult to treat   |   Read more ...



• 2006(28) Efficacy and Economics of Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis
  Atopic dermatitis is a chronic, relapsing inflammatory skin disease that frequently affects infants and children. The worldwide prevalence of atopic dermatitis is estimated to be 5-20% of the pediatric population. Studies have shown that atopic dermatitis is associated with considerable economic costs and decreased quality of life   |   Read more ...



• 2006(26) Development of a psychological treatment service for pruritic skin conditions
  The role of psychological contributions to common dermatological disease is increasingly recognized. It is often a challenge to find suitable psychological services to complement dermatological treatment. This paper describes the development of a psychological treatment service to reduce scratching behaviour found in common pruritic skin conditions   |   Read more ...



• 2006(25) Use of Calcipotriene Cream (Dovonex® Cream) Following Acute Treatment of Psoriasis Vulgaris with the Calcipotriene/Betamethasone Dipropionate Two-Compound Product (Taclonex®): A Randomized, Parallel-Group Clinical Trial
  A calcipotriene/betamethasone dipropionate two-compound product (Taclonex^® ointment) has been shown to be safe and effective in the treatment of psoriasis over 4 weeks. Since treatment of psoriasis is generally long-term   |   Read more ...



• 2006(24) Prospects for Vaccines for Allergic and Other Immunologic Skin Disorders
  The human skin hosts a variety of immune response-associated components that together form the skin immune system. Any abnormality in the functioning of the skin immune system leads to a variety of dermatologic complications, including dermatitis, psoriasis, and eczema   |   Read more ...



• 2006(23) Rosacea Fulminans in Pregnancy: Case Report and Review of the Literature
  Rosacea fulminans is a rare disease of unknown cause, which occurs exclusively in women years after adolescence. Although the etiology is unknown, immunologic, hormonal, and vascular factors have been suggested   |   Read more ...



• 2006(22) Cost Effectiveness of Management of Mild-to-Moderate Atopic Dermatitis with 1% Pimecrolimus Cream in Children and Adolescents 2-17 Years of Age
  Data on the efficacy of AD management with 1% pimecrolimus cream (Elidel^®, Novartis Pharma GmbH, Wehr, Germany) were obtained from a 12-month, randomized, double-blind, multinational, controlled clinical trial comparing pimecrolimus and conventional therapy   |   Read more ...



• 2006(21) Safety, Efficacy, and Dosage of 1% Pimecrolimus Cream for the Treatment of Atopic Dermatitis in Daily Practice
  Although several controlled clinical trials have demonstrated the efficacy and good tolerability of 1% pimecrolimus cream for the treatment of atopic dermatitis, the results of these trials may not apply to real-life usage. The objective of this study was to evaluate the safety and efficacy of a pimecrolimus-based regimen in daily practice   |   Read more ...



• 2006(20) Techniques for Soft Tissue Augmentation: An 'A to Z'.
  As society continues to seek the most opportune means to preserve youthful looks, an interest in filling substances has been reawakened. This is partly because the upper third of the face can now be successfully treated as a result of the development and recent US FDA approval of botulinum toxin (Botox^®)   |   Read more ...



• 2006(19) Receptor-Selective Retinoids for Psoriasis: Focus on Tazarotene
  The first topical receptor-selective retinoid to be approved for the treatment of plaque psoriasis is tazarotene. Topical tazarotene displays an onset of action and efficacy similar to those of other established antipsoriatic agents. Common adverse events of this agent such as pruritus, burning, local skin irritation, and erythema are limited to the skin and generally mild or moderate in severity   |   Read more ...



• 2006(18) Topical Macrolide Immunomodulators: A Role in the Treatment of Vitiligo?
  Recently, topical macrolide immunomodulators have been successfully introduced in the treatment of atopic dermatitis. With the growing interest in this new line of topical immunosuppressants, research into the efficacy of these medicines in other T-cell-mediated skin diseases   |   Read more ...



• 2006(17) Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks
  Imiquimod 5% cream is approved in the USA, Europe and Australia to treat superficial basal cell carcinoma, using a regimen of once daily, 5 times per week for 6 weeks. Vehicle-controlled, phase III clinical trials show that imiquimod is safe and effective   |   Read more ...



• 2006(16) Tretinoin Microsphere Gel 0.1% for Photodamaged Facial Skin: A Placebo-Controlled Trial
  A 63-year-old woman presented with a 6-year history of persistent cheilitis. Minimal improvement was achieved with therapeutic measures   |   Read more ...



• 2006(15) Cosmetic Dermatology - Update
  Eighteen subjects with mild to moderate photodamage were enrolled in a study to evaluate the efficacy and tolerability of a moisturizing cream containing kinetin 0.1%...; Although rhinoplasty is a popular cosmetic procedure, it is possible to reposition and reshape the nose without invasive surgery...; The popularity of mesotherapy continues to grow because of its success as an effective   |   Read more ...



• 2006(14) Tretinoin Microsphere Gel 0.1% for Photodamaged Facial Skin: A Placebo-Controlled Trial
  Tretinoin microsphere gel (TMG) 0.1% was evaluated as a treatment of photodamaged skin. The study included a 6-month, randomized, double-blinded, placebo-controlled phase and an additional 6-month open-label phase during which all subjects received TMG 0.1%   |   Read more ...



• 2006(13) National report - Two recent studies regarding isotretinoin risks
  Two recent studies regarding isotretinoin risks confirm what dermatologists have long known - that the drug can transiently raise cholesterol levels and perhaps aggravate inflammatory bowel disease (IBD). However, dermatologists express concern that lay press portrayals of these studies have raised needless alarm   |   Read more ...



• 2006(12) Retinoid therapy of pigmentary disorders
  Topical retinoids such as all-trans-retinoic acid (RA), 13-cis-retinoic acid (isotretinoin), retinol, retinaldehyde, tazarotene, and adapalene have been shown to improve dyspigmentation of photodamaged skin including mottling and actinic lentigines. RA monotherapy has also been demonstrated to improve melasma and postinflammatory hypermelanosis   |   Read more ...



• 2006(11) Retinoids in cosmeceuticals
  Retinoids are natural and synthetic vitamin A derivatives. They are lipophilic molecules and easily penetrate the epidermis. Their biologically active forms can modulate the expression of genes involved in cellular differentiation and proliferation   |   Read more ...



• 2006(10) Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients
  Systemic retinoids (isotretinoin, etretinate, and acitretin) have been shown to be effective chemotherapeutic agents in studies of patients with xeroderma pigmentosum, the nevoid basal cell carcinoma syndrome, and recipients of organ or bone marrow transplantation   |   Read more ...



• 2006(9) Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts
  Conventional ablative treatments for external anogenital warts are affected by high recurrence rates. This study compared sustained clearance after ablation vs. treatment with imiquimod 5% cream vs. the combination of both methods   |   Read more ...



• 2006(8) The effects of tea extracts on proinflammatory signaling
  Skin toxicity is a common side effect of radiotherapy for solid tumors. Its management can cause treatment gaps and thus can impair cancer treatment. At present, in many countries no standard recommendation for treatment of skin during radiotherapy exists   |   Read more ...



• 2006(7) Finasteride induced depression: a prospective study
  Finasteride is a competitive inhibitor of 5 alpha-reductase enzyme, and is used for treatment of benign prostatic hyperplasia and androgenetic alopecia. Animal studies have shown that finasteride might induce behavioral changes. Additionally, some cases of finasteride-induced depression have been reported in humans   |   Read more ...



• 2006(6) Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study
  Natural rubber latex (NRL) allergy is a worldwide problem. Although prevention is sufficient to reduce sensitization, prolonged avoidance is needed to prevent resensitization or adverse reactions on re-exposure   |   Read more ...



• 2006(5) Changes in skin barrier function following long-term treatment with moisturizers, a randomized controlled trial
  Moisturizers are commonly used by patients with dry skin conditions as well as people with healthy skin. Previous studies on short-term treatment have shown that moisturizers can weaken or strengthen skin barrier function and also influence skin barrier recovery   |   Read more ...



• 2006(4) Blinded side-to-side comparison of topical corticosteroid and tacrolimus ointment in children with moderate to severe atopic dermatitis
  There is little information on the relative efficacy of topical tacrolimus and corticosteroids in the treatment of atopic dermatitis (AD) in children. In a single-centre, prospective, observer-blinded, side-to-side comparative study   |   Read more ...



• 2006(3) Diabetes mellitus
  Dermatologic problems are common in diabetes, with approximately 30% of patients experiencing some cutaneous involvement during the course of their illness. Skin manifestations generally appear during the course of the disease in patients known to   |   Read more ...



• 2006(2) Canadian-led study evaluated Resultz™
  Oakville, Ontario - August 28, 2006 - A unique pediculicide rinse called Resultz™ that has been shown to be 96 per cent effective in treating head lice is set to arrive in pharmacies across Canada in time for the new school year, offering health care professionals a new option with which to help parents eradicate this common condition. Highly effective when used as directed, Resultz does not contain pesticides, and   Read more ...



• 2006(1) Welcome News for Patients with Acne
  The price of isotretinoin has been appreciably decreased. An unexpected but welcome announcement by Hoffmann-La Roche (Canada) they have met head on the recently announced price reduction of Prempharm’s – “Clarus” the generic – isotretinoin that was introduced a year ago!   Read more ...

    Other Archives:   Dermatology News 2007

The Derm News service provided by the Editorial Consultants of Skin Therapy Letter^© and its founding editor Dr. Stuart Maddin.